2025 ASCO|荣昌生物维迪西妥单抗一线治疗胃癌结果入选口头报告

荣昌生物
24 Apr

REMEGEN美国临床肿瘤学会2025年年会(ASCO 2025)将于5月30日至6月3日在美国芝加哥举行。ASCO年会是全球肿瘤医学领域最具权威性和影响力的学术盛会之一,每年汇聚来自世界各地的顶尖临床与科研成果。在本次大会上,荣昌生物(股票代码:688331.SH/09995.HK)20余项肿瘤管线临床进展或阶段性数据入选口头报告、壁报或线上展示,其中包括维迪西妥单抗联合疗法一线治疗HER2表达...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10